Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Richard Dicicco from Harvest Moon Pharmaceuticals USA provides an Exclusive Interview in the Run-Up to Biosimilars North America 2016

SMi Group
Posted on: 19 Aug 16
Richard Dicicco from Harvest Moon Pharmaceuticals USA provides an Exclusive Interview in the Run-Up to Biosimilars North America 2016

~~It's without doubts that the biosimilars market present lucrative opportunities for pharmaceuticals and biotech companies. Over the last 12 months, market participants have witnessed revolutionary steps in the US to facilitate commercialization.

The 3rd Annual Biosimilars North America conference will provide timely discussion with case studies on how to commercialize biosimilars, latest market developments and regulatory updates to ensure you stay at the forefront of this evolving market!
In the run up to the event, the SMi Group caught up with the conference chairman: Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc. for the exclusive interview, revealing his thoughts on biosimilars market situation in the US, approval process, regulatory framework and much more.
In the interview Richard Dicicco said about the approval process in the United States:

"We have three approved biosimilar mAb products in the US in 2016 totalling four biosimilars... FDA has optimized and streamlined the approval process...Once the sponsors are able to develop robust presentations with their data statistically presented by the FDA statisticians to the Advisory committees, approval comes quickly and unanimously. Once the insurance coverage gaps are filled, the initial biosimilar entrance will behave as branded biologics but eventually the market will become commoditized as a deeply discounted generic market from what we have seen in Europe... "

To download the full interview please visit:

Unrivalled speaker line up in 2016 will include:
- Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals
- Gustavo Grampp, Ph.D., Director R&D Policy - Biosimilars, Amgen Inc.
- Andrew Simpson, Scientifi c Director, Orygen Biotechnologia S/A
- Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US
- Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfizer Inc., and many more.
Conference will also feature two interactive pre-conference workshops:
A: Leveraging Successful Patient Recruitment & Retention Strategies in Biosimilars Research
Led by Shazia Ahmad, Director, Patient & Physician Services, UBC - An Express Scripts Company

B: Biosimilars: Considerations for Optimizing Access and Price
Led by: Mkaya Mwamburi, Vice President, HEOR/Evidence Generation, MKTX Market Access Solutions, LLC

2016 event is sponsored by: Abzena, Schwegman, Lundberg & Woessner, P.A. and Wyatt Health Management

For more information please visit:

For media enquiries please contact Anna Serazetdinova on +44 20 7827 6180 or
For delegate enquiries contact Fateja Begum +44 (0) 20 7827 6184 or email
For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email:
---- END ----
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at


For more information:

Editor's Details

Anna Serazetdinova

Last updated on: 19/08/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.